Amyris Inc (NASDAQ:AMRS)’s share price was down 5.1% during mid-day trading on Friday . The company traded as low as $2.77 and last traded at $2.82, approximately 2,726,255 shares changed hands during trading. An increase of 12% from the average daily volume of 2,435,364 shares. The stock had previously closed at $2.97.
Separately, BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has a consensus rating of “Buy” and an average target price of $9.50.
The business has a 50-day moving average price of $3.48. The company has a market cap of $232.64 million, a P/E ratio of -1.11 and a beta of 1.04.
In other Amyris news, Director Frank Kung purchased 913,529 shares of Amyris stock in a transaction on Monday, April 29th. The shares were bought at an average price of $4.76 per share, with a total value of $4,348,398.04. Following the completion of the acquisition, the director now directly owns 3,599 shares of the company’s stock, valued at $17,131.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. 21.80% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Traynor Capital Management Inc. purchased a new stake in shares of Amyris in the second quarter valued at about $38,000. SG Americas Securities LLC purchased a new stake in shares of Amyris in the first quarter valued at about $28,000. Jane Street Group LLC purchased a new stake in shares of Amyris in the fourth quarter valued at about $48,000. HRT Financial LLC purchased a new stake in shares of Amyris in the fourth quarter valued at about $52,000. Finally, American Financial Advisors LLC purchased a new stake in shares of Amyris in the first quarter valued at about $33,000. 34.17% of the stock is currently owned by institutional investors.
Amyris Company Profile (NASDAQ:AMRS)
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Further Reading: What are municipal bonds?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.